-
Medicxi-Led Investment Boosts D3 Bio’s Development of Best- in-Class Oncology Therapies
•
UK life sciences investment firm Medicxi has taken the lead in a $62 million Series A+ funding round for D3 Bio, a China-based biotech company focused on developing innovative oncology drugs. The investment, in which Medicxi contributed $40 million, will support the advancement of D3 Bio’s pipeline, including three molecules…
